Deaths are significantly less in the third wave of the Covid-19 pandemic in comparison to the second wave, and the current surge is not witnessing increase in severe illness or death following high vaccination uptake, the government said on Thursday.
A total of 25,12,388 samples have been tested for coronavirus infection as on 9 am, May 20 all over the country.
The Union health ministry on Friday said license has been given to five more manufacturers for production of Amphotericin-B, used in the treatment of black fungus, and they will start producing 1,11,000 vials of the drug per month from July.
The average Tests Per Million Per Day have increased from 237 in the second week of July to 758 in the first week of September.
Gennova has also got permission for phase-2 and 3 clinical trials for its lyophilised mRNA vaccine for injection from the subject expert committee advising the Central Drugs Standards Control Organisation, reports Sohini Das.
The COVID-19 pandemic has not only affected outpatient services, but also led to deferment of elective surgeries, and resulted in the loss of medical tourism, all of which would hit the FY21 financials.
As has been reported from states and UTs that have pushed ahead with aggressive testing, there is a commensurate decline in the positivity rate, the health ministry said.
The survey was carried out in wards R-north (Borivali), M-West (Mankhurd and Govandi) and F-North (Worli and Lower Parel) in the second half of August.
He also said that although India got independence much before Goa became free, people of the country could not enjoy at that time as they felt uneasy thinking that one part was the country was still under foreign rule.
If a retail investor wants exposure to a healthcare ETF, it should be a part of his satellite portfolio, suggests Sanjay Kumar Singh.
Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine. Sohini Das profiles its 39-year-old CEO.
PM Modi said that it was an honour to be a trusted partner during the pandemic adding that the two countries will continue to strengthen cooperation on healthcare.
Although British Prime Minister Boris Johnson has delayed the full reopening of England's economy until July 19, a week after the final, people can still gather in bars and pubs. Jubilant fans were pictured packing bars, streets and even clambering on top of a London bus in the aftermath of England's extra-time 2-1 victory over Denmark, with fan-zones highlighted by some as a particular risk for transmission.
The relentless rally in small- and mid-cap stocks continues as large-caps show signs of fatigue. In July, the Nifty Smallcap 100 rose 8.1 per cent, extending its year-to-date (YTD) gains to 48.5 per cent, while the Nifty Midcap 100 added 3.1 per cent, taking its YTD rise to 33.5 per cent. On the other hand, the Nifty50 remained unchanged for the month, with YTD gains of 12.7 per cent.
The latest variant is the most heavily mutated version discovered so far.
Fortis Healthcare Chairman Malvinder Mohan Singh on Wednesday said it planned to launch an IPO for its diagnostics business unit, Super Religare Laboratories (SRL), in 2011. SRL had acquired the diagnostics business of Piramal Healthcare for Rs 600 crore in the first quarter of this financial year.
"The recovery rate is 58.56 per cent amongst COVID-19 patients," the ministry said.
The offering comprises secondary sale of 13.68 million shares, constituting 27.3 per cent stake.
Taking lessons from that, I would think seamless digital payments is something you have to clearly have a roadmap for, the FM said.
New age diagnostic tools come in handy for BharatBenz to predict repair needs and breakdown in advance.
The new portal provides physicians with a single, easy-to-use interface that speeds up the order-to-delivery of devices, processing of diagnostic data and management of insurance claims.
'Q1 is going to bear the brunt of the second wave, exposing full-year GDP forecasts to downward revisions, unless phase-3 of vaccination is executed quickly.'
Maharashtra Chief Minister Uddhav Thackeray announced a statewide curfew for 15 days from 8 am on April 14 to contain the rapid spread of the coronavirus in its second wave. With Section 144 being imposed across the state, Thackeray essential services have been exempted from the restrictions. The curfew will be in place till 7 am on May 1.
The buzz in the IPO market continues with four companies launching their initial share sales this week to raise over Rs 14,628 crore collectively. This comes after four companies -- Devyani International, Krsnaa Diagnostics, Windlas Biotech and Exxaro Tiles-- launched their initial share-sales last week to mobilise Rs 3,614 crore. So far in the current fiscal, 16 companies have raised Rs 30,666 crore through IPOs against Rs 31,277 crore by 30 firms in the entire 2020-21. Going forward, market analysts expect the IPO environment to remain buzzing during the entire 2021-22.
Raj Barathur -- Indian American entrepreneur, geneticist, professor and biopharmaceutical industry leader -- stayed the course even when diagnosed with lung cancer
NITI Aayog CEO Amitabh Kant shared ten best practices in a bid to bolster India's efforts against Covid-19 pandemic.
8 Asiatic lions in the zoo in have tested positive for COVID-19 after their saliva samples were thoroughly examined by CSIR-Centre for Cellular and Molecular Biology in Hyderabad, Rakesh Mishra, advisor of the premier research institute said.
The Union health ministry is releasing funds for states and Union territories under the National Health Mission for implementation of phase 1 up to June 2020.
Two kinds of diagnostic tests are being currently used in India -- RT-PCR test and rapid antibodies test -- as per the global health norms.
This train in Russia is a free consultative and diagnostic medical centre.
The government on Wednesday approved a production-linked incentive (PLI) scheme for the pharmaceutical sector, entailing an outlay of Rs 15,000 crore. The Union Cabinet, chaired by Prime Minister Narendra Modi, approved the scheme which will benefit domestic manufacturers, help create employment and is expected to contribute to the availability of a wider range of affordable medicines for consumers. The duration of the scheme would be from 2020-21 to 2028-29 and is expected to promote the production of high value products in the country and increase the value addition in exports, an official release said.
India has come a long way from conducting the first COVID-19 test in January in a laboratory in Pune to crossing the milestone of conducting four crore such tests.
A total of 5,15,385 COVID-19 patients have recovered so far with 19,870 patients having been cured and discharged in the last 24 hours till 8 am.
After business, knowledge and legal process outsourcing, the Indian industries are now eyeing 'diagnostics jobs' outsourcing from other countries. According to industry experts, a number of hospitals in the US and Europe are outsourcing laboratory and diagnostic tests to India as it helps in saving cost and money while maintaining quality.
Soumya Swaminathan called on governments to boost exercises on reporting actual numbers.
The Central Board of Secondary Education (CBSE) announced on Tuesday the schedule for classes 10 and 12 board exams which will begin on May 4.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
In a tweet, Prime Minister Narendra Modi said India is deeply honoured to be a 'long-trusted' partner in meeting the healthcare needs of the global community and that supplies of the vaccines to several countries will commence on Wednesday, and more will follow in the days ahead.
It designs microsurgical instruments, devices used in minimally invasive surgery, drug delivery devices for ophthalmic therapies and user-centric wearables.
The study, published in the journal Nature Structural & Molecular Biology, noted that the 'nanobodies' can prevent infection with the novel coronavirus SARS-CoV-2 by blocking its interaction with the protein ACE2, which it uses as a gateway to enter and infect cells.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances